If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-01-16. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
In 1929, Adolf Butenandt and Edward Adelbert Doisy independently isolated and purified estrone, the first estrogen to be discovered. Then, estriol and estradiol were discovered in 1930 and 1933, respectively. Shortly following their discovery, estrogens, both natural and synthetic, were introduced for medical use. Examples include estriol glucuronide (Emmenin, Progynon), estradiol benzoate, conjugated estrogens (Premarin), diethylstilbestrol, and ethinylestradiol. The word estrogen derives from Ancient Greek. It is derived from "oestros" (a periodic state of sexual activity in female mammals), and genos (generating). It was first published in the early 1920s and referenced as "oestrin". With the years, American English adapted the spelling of estrogen to fit with its phonetic pronunciation.
In either case, a mixture of unbound ligands, proteins, ligand-protein complexes is passed through a column of porous beads. Ligand-protein complexes are excluded from entering the beads and exit the column quickly, while unbound ligands must travel through the beads and are retained by the column for a longer time. Ligands that elute from the column early on are therefore inferred to be bound to a protein. The automated ligand identification system (ALIS), developed by Schering-Plough, uses a combined HPLC-based SEC to liquid chromatography-mass spectrometry (LC-MS) system that separates ligand-protein complexes from unbound ligands using SEC and diverts the complex toward an LC-MS system for on-line analysis of bound ligands. Novartis' SpeedScreen uses SEC in 96-well spin column format, also known as gel filtration chromatography, which allows for simultaneous removal of unbound ligands from up to 96 samples. Samples are also passed through porous beads, but centrifugation is used to move the sample through the column. SpeedScreen is not coupled to an LC-MS system and requires further processing prior to final analysis. In this case, ligands must be freed from their targets and analyzed separately.
=== Chemical synthesis === Due to its very large and complex structure, synthesizing α-bungarotoxin has represented a great challenge for synthetic chemists. [16] A study conducted by O. Brun et al. proposed a mechanism for the chemical synthesis of this neurotoxin. It involves a strategy utilizing peptide fragments and native chemical ligation (NCL). Due to its length, synthesizing a full linear peptide using solid-phase peptide synthesis (SPPS) is not achievable, thus, the synthesis was done by choosing three peptide fragments that can further undergo the native chemical ligation. This method produces a native peptide bond between two fragments by reacting thioester (C-terminal) with cysteine (N-terminal). The synthesis strategy employed was from the C-terminus towards the N-terminus. Firstly, the shorter peptide fragments are synthesized via automated SPPS. The first two peptides have a Trp-Cys ligation point, while the ligation with the last fragment occurs in a Gly-Cys ligation point. Additionally, in this study, an alkyne functionality was introduced at the N-terminus of the peptide chain. This allows the conjugation of different molecules such as fluorophores via bioorthogonal reactions. By fluorescently labelling the chemically synthesised peptide it was shown it has the same effect and functionality on the nicotinic receptors as the naturally occurring α-bungarotoxin.
Sources: en.wikipedia.org
=== Gelatin-based scaffolds === Gelatin is the denatured form of collagen. Gelatin possesses several advantages for tissue-engineering application: they attract fibroblasts, are non-immunogenic, easy to manipulate and boost the formation of epithelium. There are three types of gelatin-based scaffolds:
=== Short-term === The high short-term radioactivity of spent nuclear fuel is primarily from fission products with short half-life. The radioactivity in the fission product mixture is mostly due to short-lived isotopes such as 131I and 140Ba, after about four months 141Ce, 95Zr/95Nb and 89Sr constitute the largest contributors, while after about two or three years the largest share is taken by 144Ce/144Pr, 106Ru/106Rh and 147Pm. Note that in the case of a release of radioactivity from a power reactor or used fuel, only some elements are released. As a result, the isotopic signature of the radioactivity is very different from an open air nuclear detonation where all the fission products are dispersed.
Freeze-dried foods became a major component of astronaut and military rations. What began for astronaut crews as tubed meals and freeze-dried snacks that were difficult to rehydrate, were transformed into hot meals by improving the process of rehydrating freeze-dried meals with water. As technology and food processing improved, NASA looked for ways to provide a complete nutrient profile while reducing crumbs, disease-producing bacteria, and toxins. The crumb problem was solved with the addition of a gelatin coating on the foods to lock in and prevent crumbs. The complete nutrient profile was improved with the addition of an algae-based vegetable-like oil to add polyunsaturated fatty acids. Polyunsaturated fatty acids are beneficial in mental and vision development and, as they remain stable during space travel, can provide astronauts with added benefits. Disease-producing bacteria and toxins were reduced by quality control and the development of the Hazard Analysis and Critical Control Points (HACCP) plan, which is widely used today to evaluate food material before, during, and after processing. With the combination of these three innovations, NASA could provide safe and wholesome foods to their crews from freeze-dried meals. Military rations have also come a long way, from being served cured pork and corn meal to beefsteaks with mushroom gravy. How rations are chosen and developed is based on acceptance, nutrition, wholesomeness, producibility, cost, and sanitation.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.